Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults With Hypereosinophilic Syndrome (HES)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 10 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Depemokimab (Primary)
Indications Hypereosinophilic syndrome
Focus Registrational; Therapeutic Use
Acronyms DESTINY
Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK

Most Recent Events

25 Nov 2025 Planned End Date changed from 30 Nov 2026 to 19 Dec 2028.
25 Nov 2025 Planned primary completion date changed from 2 Nov 2026 to 19 Dec 2028.
22 Apr 2025 Planned number of patients changed from 120 to 123.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com